Discovery of a potent FKBP38 agonist that ameliorates HFD-induced hyperlipidemia via mTOR/P70S6K/SREBPs pathway
The mammalian target of rapamycin (mTOR)-sterol regulatory element-binding proteins (SREBPs) signaling promotes lipogenesis. However, mTOR inhibitors also displayed a significant side effect of hyperlipidemia. Thus, it is essential to develop mTOR-specific inhibitors to inhibit lipogenesis. Here, we...
Saved in:
Main Authors: | Ping-Ting Xiao (Author), Zhi-Shen Xie (Author), Yu-Jia Kuang (Author), Shi-Yu Liu (Author), Chun Zeng (Author), Ping Li (Author), E-Hu Liu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Laminaria japonica Aresch-Derived Fucoidan Ameliorates Hyperlipidemia by Upregulating LXRs and Suppressing SREBPs
by: Yan Zhang, et al.
Published: (2024) -
Wuwei Qingzhuo San Ameliorates Hyperlipidemia in Mice Fed With HFD by Regulating Metabolomics and Intestinal Flora Composition
by: Shasha Ge, et al.
Published: (2022) -
Corrigendum to "Dihydroartemisinin ameliorates retinal vascular dysfunction in diabetes mellitus via the FASN/Kmal-mTOR/SREBP1 feedback loop" [Pharmacol. Res. 174 (2021) 105871]
by: Chufeng Gu, et al.
Published: (2022) -
PPARδ agonist protects against osteoarthritis by activating AKT/mTOR signaling pathway-mediated autophagy
by: Guantong Sun, et al.
Published: (2024) -
Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
by: Hua Cai, et al.
Published: (2023)